Novo Nordisk Strikes Up to $2.1B Vivtex Deal for Oral Obesity Drugs [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
This article first appeared on GuruFocus Novo Nordisk A/S ( NVO Financials ) has agreed to a partnership worth up to $2.1 billion with Boston-based Vivtex Corporation to develop next-generation oral biologic therapies targeting obesity, diabetes and related metabolic disorders. Warning! GuruFocus has detected 2 Warning Sign with NVO. Is NVO fairly valued? Test your thesis with our free DCF calculator. Novo will be in charge of worldwide research and commercialization, and Vivtex will provide its own oral drug delivery technology. The technique is meant to make it possible for biologic drugs, which are usually given by injection, to be taken in tablet form. This might make it easier for patients to take their medications and stick to their treatment plans. The partnership is in line with Novo's plan to extend its leadership in the quickly growing diabetes and obesity industries, where demand for GLP-1based medicines is still rising. Oral biologics might provide a company an
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Novo Nordisk Shares Sink 21% as Obesity Shot Trails Lilly Rival [Yahoo! Finance]Yahoo! Finance
- SA analyst upgrades/downgrades: NVDA, NKE, SMCI, NVO [Seeking Alpha]Seeking Alpha
- Clinical ink Appoints Dr. Christian Born Djurhuus, MD, PhD as Chief Science OfficerPR Web
- Novo Nordisk's Torrid Week Erases Last of Wegovy-Fueled Gains [Yahoo! Finance]Yahoo! Finance
- 12 Press Releases You Need to See This Week [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 2/23/26 - Form 6-K
- 2/23/26 - Form 6-K
- 2/20/26 - Form 6-K
- NVO's page on the SEC website